CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned a consensus recommendation of “Hold” from the nineteen brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $74.94.

A number of research analysts have issued reports on the stock. Truist Financial reduced their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Chardan Capital cut their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th.

CRISPR Therapeutics Stock Up 7.8 %

CRSP stock opened at $55.15 on Tuesday. The company has a market cap of $4.71 billion, a price-to-earnings ratio of -19.49 and a beta of 1.67. The business has a fifty day simple moving average of $48.30 and a 200-day simple moving average of $51.58. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period last year, the business posted ($1.41) EPS. As a group, analysts expect that CRISPR Therapeutics will post -5.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently made changes to their positions in CRSP. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC boosted its position in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics in the second quarter valued at about $35,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of CRISPR Therapeutics during the third quarter valued at about $40,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.